These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 18326076

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Thrombopoietin receptor agonists in immune thrombocytopenia of less than 6 months duration.
    Arumugaswamy A, He S, Quach H, Brotchie J, Grigg A.
    Intern Med J; 2014 May; 44(5):519-21. PubMed ID: 24816314
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. What is publication? The case of eltrombopag.
    Benham L, Guo L, Turner R.
    Lancet; 2011 Jan 29; 377(9763):360-1. PubMed ID: 21277427
    [No Abstract] [Full Text] [Related]

  • 8. Immune thrombocytopenic purpura--from agony to agonist.
    Schwartz RS.
    N Engl J Med; 2007 Nov 29; 357(22):2299-301. PubMed ID: 18046034
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Eltrombopag in chronic idiopathic thrombocytopenic purpura and HCV-related thrombocytopenia.
    Panzer S.
    Drugs Today (Barc); 2009 Feb 29; 45(2):93-9. PubMed ID: 19343229
    [Abstract] [Full Text] [Related]

  • 11. Thrombopoietin-receptor agonists in children with immune thrombocytopenia.
    Neunert CE, Grace RF.
    Lancet; 2015 Oct 24; 386(10004):1606-9. PubMed ID: 26231462
    [No Abstract] [Full Text] [Related]

  • 12. Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia.
    Al-Samkari H, Kuter DJ.
    Br J Haematol; 2018 Oct 24; 183(2):168. PubMed ID: 29978577
    [No Abstract] [Full Text] [Related]

  • 13. Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience.
    Özdemirkıran F, Payzın B, Kiper HD, Kabukçu S, Akgün Çağlıyan G, Kahraman S, Sevindik ÖG, Ceylan C, Kadıköylü G, Şahin F, Keskin A, Arslan Ö, Özcan MA, Kabukçu G, Görgün G, Bolaman Z, Büyükkeçeci F, Bilgir O, Alacacıoğlu İ, Vural F, Tombuloğlu M, Gökgöz Z, Saydam G.
    Turk J Haematol; 2015 Dec 24; 32(4):323-8. PubMed ID: 25914025
    [Abstract] [Full Text] [Related]

  • 14. Use of Thrombopoietin-Receptor Agonist in CVID-Associated Immune Thrombocytopenia.
    Carrabba M, Barcellini W, Fabio G.
    J Clin Immunol; 2016 Jul 24; 36(5):434-6. PubMed ID: 27072856
    [No Abstract] [Full Text] [Related]

  • 15. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
    Grainger JD, Locatelli F, Chotsampancharoen T, Donyush E, Pongtanakul B, Komvilaisak P, Sosothikul D, Drelichman G, Sirachainan N, Holzhauer S, Lebedev V, Lemons R, Pospisilova D, Ramenghi U, Bussel JB, Bakshi KK, Iyengar M, Chan GW, Chagin KD, Theodore D, Marcello LM, Bailey CK.
    Lancet; 2015 Oct 24; 386(10004):1649-58. PubMed ID: 26231455
    [Abstract] [Full Text] [Related]

  • 16. Successful discontinuation of eltrombopag in one child with refractory primary immune thrombocytopenia and literature review.
    Wang X, Liu X, Wang L, Wang JY, Li A.
    Blood Coagul Fibrinolysis; 2019 Mar 24; 30(2):71-74. PubMed ID: 30720490
    [Abstract] [Full Text] [Related]

  • 17. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.
    Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, Kloczko J, Hassani H, Mayer B, Stone NL, Arning M, Provan D, Jenkins JM.
    N Engl J Med; 2007 Nov 29; 357(22):2237-47. PubMed ID: 18046028
    [Abstract] [Full Text] [Related]

  • 18. Eltrombopag: an oral thrombopoietin receptor agonist for the treatment of idiopathic thrombocytopenic purpura.
    Zhang Y, Kolesar JM.
    Clin Ther; 2011 Nov 29; 33(11):1560-76. PubMed ID: 22054810
    [Abstract] [Full Text] [Related]

  • 19. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study.
    Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL, Bussel JB.
    Lancet; 2011 Jan 29; 377(9763):393-402. PubMed ID: 20739054
    [Abstract] [Full Text] [Related]

  • 20. Effectiveness of thrombopoietin-receptor agonists in the treatment of refractory immune thrombocytopenia associated to systemic lupus erythematosus.
    Magnano L, Enríquez H, Esteve J, Cervera R, Espinosa G.
    J Rheumatol; 2014 Sep 29; 41(9):1895-6. PubMed ID: 25179983
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.